Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | SVP, GM - Oncology | November 15, 2017 | November 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date November 15, 2017 · Filed November 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,754 |
Ending reported balance
After 2017-11-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-11-15 · Exercise / conversion · Acquired 10,000 · Balance 30,754 Row 2 · 2017-11-15 · Exercise / conversion · Acquired 17,409 · Balance 48,163 Row 3 · 2017-11-15 · Sale · Disposed 27,409 · Balance 20,754 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.63 · Expires 2019-08-03 | Direct | 0 |
Reported balance
After 2017-11-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-11-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: Options for one-fourth of the shares became exercisable on 8/3/2013, 8/3/2014, 8/3/2015 and 8/3/2016, respectively. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.92 · Expires 2020-08-06 | Direct | 0 |
Reported balance
After 2017-11-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-15 · Exercise / conversion · Disposed 17,409 · Balance 0 F2: Options for one-fourth of the shares became exercisable on 8/6/2014, 8/6/2015, 8/6/2016 and 8/6/2017, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Options for one-fourth of the shares became exercisable on 8/3/2013, 8/3/2014, 8/3/2015 and 8/3/2016, respectively.
F2: Options for one-fourth of the shares became exercisable on 8/6/2014, 8/6/2015, 8/6/2016 and 8/6/2017, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2017 Filed Nov 17, 2017 21:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,409 | $0.00 Strike: $11.92 | $0.00 |
DisclosureSEC source: 0001140361-17-043208 · doc1.xml · derivative · entry 5 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,409 shares Expires 2020-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/6/2014, 8/6/2015, 8/6/2016 and 8/6/2017, respectively. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0001140361-17-043208 · doc1.xml · derivative · entry 4 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/3/2013, 8/3/2014, 8/3/2015 and 8/3/2016, respectively. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | SaleCommon Stock | 27,409 | $16.29 | $446,492.61 |
DisclosureSEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 3 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,754 Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 17,409 | $11.92 | $207,515.28 |
DisclosureSEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 2 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:08 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 10,000 | $10.63 | $106,300.00 |
DisclosureSEC source: 0001140361-17-043208 · doc1.xml · nonDerivative · entry 1 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2017 Filed Aug 8, 2017 21:46 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 502 | $16.56 | $8,313.12 |
DisclosureSEC source: 0001140361-17-030641 · doc1.xml · nonDerivative · entry 1 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,754 F1 · shares: The exempt disposition of 502 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on August 6, 2013. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantPerformance Right · Derivative | 7,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029089 · doc1.xml · derivative · entry 5 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires not disclosed F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,818 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001140361-17-029089 · doc1.xml · derivative · entry 4 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,818 Underlying: Common Stock · 12,818 shares Expires 2027-07-26 F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 19:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 3,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029089 · doc1.xml · nonDerivative · entry 3 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,256 F3 · shares: This acquisition of 3,648 shares of Common Stock represents 3,648 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021. Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 19:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 432 | $17.12 | $7,395.84 |
DisclosureSEC source: 0001140361-17-029089 · doc1.xml · nonDerivative · entry 2 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,608 F2 · shares: The exempt disposition of 432 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 25, 2014. Read SEC document |
| July 22, 2017 Filed Jul 28, 2017 19:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 393 | $16.80 | $6,602.40 |
DisclosureSEC source: 0001140361-17-029089 · doc1.xml · nonDerivative · entry 1 Richard Stark · CIK 0001539142 · SVP, GM - Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,040 F1 · shares: The exempt disposition of 393 shares of common stock ("Common Stock") of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 22, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.